Emerging Agents for Basal Cell Carcinoma and Cutaneous Squamous-Cell Carcinoma

Omid Hamid, MD, and Morgana Freeman, MD, discuss emerging systemic therapy options for the treatment of basal cell carcinoma and cutaneous squamous-cell carcinoma.

Gain perspectives from experts on various policy issues and therapeutic areas through our Insights series that engages multiple managed care stakeholders in video interviews.

Future of BCC and CSCC Therapy
December 18, 2019 – 
Final thoughts on unmet needs in the management of BCC and CSCC and how to approach future treatment of these diseases.
Second-Line Systemic Treatment of BCC
December 18, 2019 – 
Second-line therapy options for BCC treatment are reviewed, and current clinical trials on cemiplimab and pembrolizumab are evaluated.
Systemic Therapy in BCC
December 18, 2019 – 
The safety and efficacy of hedgehog inhibitors sonidegib and vismodegib are examined in the systemic treatment of BCC.
Overview of Cutaneous Squamous Cell Carcinoma
December 18, 2019 – 
An overview of cutaneous squamous cell carcinoma (CSCC), including diagnosis, distinguishing CSCC from head and neck cancer, and risk factors for developing advanced disease.
Electing for Surgery in the Management of BCC
November 04, 2019 – 
Experts provide insight on when patients may not be surgical candidates and potential complications that can follow surgery when approaching treatment of basal cell carcinoma.
Overview of Basal Cell Carcinoma
November 04, 2019 – 
An overview of basal cell carcinoma considering differential diagnoses and the current standard of care.
Toxicity Profile and Pseudoprogression
October 28, 2019 – 
A closer look into the adverse effect profile and pseudoprogession of immunotherapy when treating patients with CSCC.
PD-1 and Other Systemic Treatment Options for CSCC
October 28, 2019 – 
Key opinion leaders discuss the positive impact of cemiplimab in their personal practices along with the off-label use of pembrolizumab and cetuximab in CSCC management.
Using Immunotherapy in CSCC
October 21, 2019 – 
The benefit of using immunotherapy for the treatment of CSCC and a review of cemiplimab in Study 1540.
Systemic Treatment of CSCC
October 21, 2019 – 
Experts discuss the primary goals of therapy for nonsurgical candidates and the impact of immunotherapy for patients with advanced or metastatic CSCC.
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.